Novel pyrimidoindolone compounds are disclosed. Methods of using the pyrimidoindolone compounds and compositions containing the compounds in the treatment and/or prevention of disease and other conditions related to inflammation, neurodegeneration, osteoarthritis and apoptosis are also disclosed.
Novel pyrimidoindolone compounds are disclosed. Methods of using the pyrimidoindolone compounds and compositions containing the compounds in the treatment and/or prevention of disease and other conditions related to inflammation, neurodegeneration, osteoarthritis and apoptosis are also disclosed.
3,4-Dihydropyrimido(1,2-a)indol-10(2H)-ones as potent non-peptidic inhibitors of caspase-3
作者:Lisa M. Havran、Dan C. Chong、Wayne E. Childers、Paul J. Dollings、Arlene Dietrich、Boyd L. Harrison、Vasilios Marathias、Gregory Tawa、Ann Aulabaugh、Rebecca Cowling、Bhupesh Kapoor、Weixin Xu、Lidia Mosyak、Franklin Moy、Wah-Tung Hum、Andrew Wood、Albert J. Robichaud
DOI:10.1016/j.bmc.2009.09.036
日期:2009.11
Cysteine-dependant aspartyl protease (caspase) activation has been implicated as a part of the signal transduction pathway leading to apoptosis. It has been postulated that caspase-3 inhibition could attenuate cell damage after an ischemic event and thereby providing for a novel neuroprotective treatment for stroke. As part of a program to develop a small molecule inhibitor of caspase-3, a novel series of 3,4-dihydropyrimido(1,2-a)indol-10(2H)-ones (pyrimidoindolones) was identified. The synthesis, biological evaluation and structure-activity relationships of the pyrimidoindolones are described. (C) 2009 Elsevier Ltd. All rights reserved.